The Kuopio-based healthtech startup Adamant Health has secured €2.2 million from the German pharma and healthcare producer Gerresheimer. The companies join their forces to improve the quality of life for people with Parkinson’s disease, ArcticStartup reports.
- Founded in 2020 by Paulus Carpelan and Saara Rissanen, Adamant Health offers a technology to analyze Parkinson’s disease symptoms based on academic research. With this technology, the clinician obtains detailed information about the patient’s symptoms within a few days and can optimize treatment accordingly.
- The €2.2 million seed funding comes from the leading global pharmaceutical company Gerresheimer. It was founded as early as 1864 and has over 10,000 employees worldwide. The existing investors Voima Ventures and Cor Group and several business angels also joined in the round.
“Our investment will help drive the further development of Adamant’s unique technology and service. At the same time, it is part of our strategic expansion into innovative, platform-based drug delivery devices and digital disease monitoring,”
Dietmar Siemssen, CEO of Gerresheimer on the funding.
- In December 2020, Adamant Health raised its pre-seed round for an undisclosed amount. Voima Ventures led the round, Cor Group participated. So far, the startup has secured €2.2 million and is looking for another €800,000 to close the round.
- The fresh funding will pave the way for Adamant Health’s technology to reach new markets and help more people with movement disorders.
